Telomir Pharmaceuticals, Inc. (TELO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | - | - |
| Research and development expenses | 42,839 | 336,996 | 627,434 | 594,801 |
| General and administrative expenses | 5,027,071 | 1,850,786 | 5,378,744 | 879,695 |
| Related party travel costs | - | - | - | - |
| Total operating costs | 5,069,910 | 2,187,782 | 6,006,178 | 1,474,496 |
| Interest income | 1,362 | - | - | - |
| Interest expense | 1,342 | - | - | - |
| Interest income (expense), net | - | 7,954 | - | - |
| Interest income | - | - | 15,445 | 25,493 |
| Nonoperating income (expense) | - | - | 15,445 | - |
| Net loss | -5,069,890 | -2,179,828 | -5,990,733 | -1,449,003 |
| Basic loss per share | 0.17 | -0.07 | -0.2 | -0.05 |
| Diluted loss per share | 0.17 | -0.07 | -0.2 | -0.05 |
| Weighted average common stock shares outstanding - basic | 30,010,165 | 29,762,671 | 29,609,814 | 29,609,814 |
| Weighted average common stock shares outstanding - diluted | 30,010,165 | 29,762,671 | 29,609,814 | 29,609,814 |